Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

NCT05751668 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

98

Enrollment

OTHER

Sponsor class

Stopped Interim analysis

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Chemotherapy-Induced Peripheral Neuropathy
Metastatic Breast Carcinoma

Interventions

DRUG: Paclitaxel
DRUG: Monosialotetrahexosylganglioside
OTHER: Questionnaire Administration
OTHER: Quality-of-life assessment
DRUG: Placebo Administration

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]